Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring <i>ALK-IGFBP5</i> fusion. This evidence concerns the gene IGFBP5 and inflammatory myofibroblastic tumor.